Drugs that target the noradrenergic system may improve cognition and apathy in patients with dementia or mild cognitive impairment caused by Alzheimer’s disease but have little effect on attention or episodic memory, researchers reported.
Michael C. B. David, MBBS, a research fellow and PhD candidate at Imperial College London, and colleagues aimed to assess the efficacy of drugs with principally noradrenergic action on cognition and neuropsychiatric symptoms in patients with AD.
Researchers searched MEDLINE, Embase and ClinicalTrials.gov from 1980 to December 2021 and generated pooled